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Introduction
Thalassemia is the most widespread recessive disease
worldwide (Ryan et al. 2010; Weatherall and Clegg 2001).
Beta-thalassemia is characterized by the deficiency or ab-
sence of beta globin production. The condition is clinically
mild in the healthy carrier that can be easily detected
through routine blood testing, but intermediate or severe in
the patients who are born with 25 % chance at each preg-
nancy from parents who are both healthy carriers.
Thalassemia carriers are today present worldwide with
high frequencies mainly in the endemic countries of Africa,
the Middle East, the Indian subcontinent, Southeast Asia, and
the Mediterranean region (Fucharoen andWinichagoon 2007;
AlHamdan et al. 2007; Sarper et al. 2009). Thalassemia is a
common disease in Iran with higher frequencies in the north
and south parts of the country (Haddow 2005; Samavat and
Modell 2004; Moafi et al. 2010).
Thalassemia major leads to serious medical, social, and
economic problems for patients and their families, and pa-
tient’s care represents a considerable financial burden for the
public health budget (Verma et al. 2011; Langlois et al.
2008). After a 5-year pilot screening, the Iranian Ministry
of Health approved in 1996 a mandatory national screening
protocol for premarital testing. This program included a
laboratory strategy to identify and counsel couples at risk
providing support and care (Samavat and Modell 2004;
Iranian Health 2004). Although compared to other regions,
the Isfahan province can be considered an area at moderate
prevalence; premarital screening was locally started in 1992
and gradually extended to the entire province by 1997
(Zeinalian et al. 2009). This report presents the results of
the premarital screening program applied in the Isfahan
province during the last two decades (1992–2010).
Material and methods
With more than 4,500,000 people, the Isfahan Province is
the second in Iran. It is situated in the central part of the
country (Fig. 1). The province is divided into 22 districts
with a state center for thalassemia screening and genetic
counseling in each and every district. After pilot studies in
Isfahan and other districts in 1997, all couples within the
province who applied for marriage were screened for beta-
thalassemia. Although the screening was mandatory, in-
formed couples were generally willing to be tested and
comprehensive guidelines were prepared and distributed to
all involved in the program by the Public Health Ministry.
According to these guidelines, screening tests included com-
plete blood count first for the male partner and eventually
for the female if the male had low blood indices. A standard
premarital questionnaire included name, sex, age, address,
and telephone number. The subjects could be considered
potential carriers of beta-thalassemia if their mean corpus-
cular volume (MCV) was lower than 80 fL and/or the mean
corpuscular hemoglobin (MCH) was less than 27 pg. If both
partners of a couple present low blood indices, their hemo-
globin A2 will be measured by manual column chromatog-
raphy as from international recommendations (Stephens et
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al. 2012). The beta-thalassemia trait will be considered
present if the hemoglobin A2 is more than 4 %. For cases
between 3.5 and 4 % with microcytic parameters in both
partners, they will be classified as a possible beta-or alpha
thalassemia couple. When both partners have low blood
indices and their hemoglobin A2 is less than 3.5 %, iron
therapy is prescribed for 1–3 months. After this period, if
their blood indices are normalized, their condition can be
attributed to iron deficiency. If their blood indices are not
improved after iron-therapy period and their hemoglobin A2
is above 3.5 %, they will be classified as suspected couple at
risk (Iranian Health 2004).
Comprehensive genetic counseling is offered to all proved
or suspected couples at risk by teams trained in genetic
counseling centers. If the couples decide to marry, they are
referred to urban or rural health centers within the support
system to assist them in family planning and genetic testing as
long as they are fertile. Prenatal genetic testing technology has
been established in Iran since 1999 (Najmabadi et al. 2006).
Before 1999, genetic counseling for thalassemia was
aimed at convincing couples at risk not to marry. After
1999, prenatal diagnosis and genetic counseling have be-
come available in Iran leading to approximately 1,000 fewer
thalassemia major births per year in the whole of the country
(Iranian Health 2008).
In particular, a network of 97 rural health centers, 166
urban health centers, 22 screening laboratories, and 22 ge-
netic counseling clinics are assigned to provide testing,
counseling and care services for all potential couples in the
Isfahan Province.
All data have been collected according to the local ethical
regulation and anonymously analyzed using SPSS-19 and
Microsoft Excel softwares.
Results
Out of the 703,082 couples screened in this period, 1,317
(0.19 %) were classified as at risk (i.e., both partners were
beta thalassemia carriers with Hb A2>3.5 %) while 4,412
(0.63 %) remained suspected (at risk) (Table 1 and Fig. 2).
Suspected couples were followed up to 2009 providing
prenatal genetic testing to about 94 % of them and confirming
their status in 19 % of the couples as carrier couples of beta-
thalassemia trait. Using this information, the rate of thalasse-
mia trait in screened couples was calculated to be about
0.31 % ((0.63 %×0.19)+0.19 % ).
During the first 8 years (before setting up genetic testing),
the average rate of marriage renounce among presumed
couples at risk was 45 % while it dropped to 13 % after
Fig. 1 Isfahan province
location on Iran’s map
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setting up genetic testing. For confirmed couples at risk,
marriage renouncing dropped from 60.2 % in the first year
to 9.4 % in the last year of the study (Fig. 3).
In total, 661 couples at risk were followed by the health
system until the end of 2010. By the end of our study,
genetic testing was performed for 560 couples (85 %)
against 6.9 % in the first year of testing (2005) (Fig. 4).
Five hundred eleven couples (77 %) were tested within the
premarital screening program, 124 (19 %) were parents of
the current patients who were still fertile and seeking
healthy offspring, and 26 (4 %) had been detected before
starting the program (they had been screened passively by
healthcare system). During the last 5 years of the program,
the pregnancy of 92 fetuses affected with beta-thalassemia
major was terminated by therapeutic abortion.
In total in the Isfahan Province, 109 beta-thalassemia major
cases have been born from the start of the national premarital
screening in 1997 and 2010. So, the birth prevalence has
decreased from 41.3 cases per 100,000 live births in 1997 to
1.5 cases per 100,000 live births at 2010 (Fig. 5). The most
prevalent reasons for the births of the affected children were:
marriage before the start of the program (51 %), culture-
related causes (15 %), wrong counseling (9 %), and mistakes
in the healthcare organization (6 %) (Table 2).
Table 1 Summary of premarital screening program for beta-thalassemia in central part of Iran
Year Number of
screened
couples
Screened couples BOTH
with thalassemia trait
Suspected couples Number of
marriage
refusal
Percent of
marriage
refusal
Number of
under care
carrier couples
Number of
couples with
PND1
Number Percent Number Percent
1992 15,252 21 0.14 67 0.44 53 60.2 24 0
1993 16,218 23 0.14 86 0.53 61 56 52 0
1994 17,256 25 0.14 104 0.60 59 45.7 94 0
1995 18,274 24 0.13 121 0.66 66 45.5 131 0
1996 19,625 28 0.14 134 0.68 85 52.5 159 0
1997 34,015 65 0.19 217 0.64 142 50.4 196 0
1998 36,967 72 0.19 231 0.62 139 45.9 201 0
1999 38,422 76 0.20 245 0.64 94 29.3 207 0
2000 39,627 77 0.19 238 0.60 58 18.4 215 0
2001 40,572 81 0.20 246 0.61 61 18.7 221 2
2002 41,156 85 0.21 259 0.63 55 16 234 4
2003 42,356 82 0.19 268 0.63 61 17.4 252 7
2004 43,659 85 0.19 272 0.62 56 15.7 286 15
2005 45,122 91 0.20 288 0.64 45 11.9 306 21
2006 46,792 95 0.20 285 0.61 29 7.6 337 45
2007 52,080 105 0.20 296 0.57 50 12.5 376 70
2008 51,158 91 0.18 314 0.61 45 11.1 442 314
2009 53,182 85 0.16 323 0.61 24 5.9 584 450
2010 51,349 106 0.21 418 0.81 49 9.4 661 560
total 70,3082 1,317 0.19 4,412 0.63 1,232 21.5
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Fig. 2 Comparative frequency
of screened couples with beta-
thalassemia trait and suspected
couples in Isfahan Province
within 1992–2010
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Discussion
Screening in Iran
According to an Iranian law from 1997, screening and
genetic counseling documents are needed for an official
marriage registration. As a consequence, the Iranian
premarital screening program for β-thalassemia started in
1997, preceded only by a few Middle East countries like
Bahrain (1985) and Turkey (1995). In contrast with the most
of endemic European countries where screening is since the
1970s in most cases an optional service (Alswaidi and
O’Brien 2009), premarital screening programs as a manda-
tory rule has been applied from 2000 in the majority of the
Middle East’s countries.
In Isfahan, the compliance of obligatory premarital
screening has been almost complete since only three cases
of marriage without premarital screening have been reported
in the period between 2001 and 2011. Due to such a strict
rule, a large number of couples have renounced marriage
during the first years of the program, before genetic testing
became available in Iran. In a previous study over the period
between 1997 and 2001, out of 2.7 million couples screened
all over Iran 10,290 were suspected at risk (0.4 %) and in
29 % of the cases the couple renounced to marry (Samavat
and Modell 2004).
In another study in southern Iran on about 1.04 million
couples between 1995 and 2004, 0.4 % of them were iden-
tified as carriers and 37 % did not marry after screening
(Karimi and Rasekhi 2002).
Moreover, due to uncertain situations regarding health
insurance and high costs related to genetic testing, the option
not to marry has gone on during the years also after the
introduction of molecular analysis and prenatal diagnosis.
Many reports have shown that molecular analysis needs a
thorough knowledge on the spectrum of mutations present
in the area. Specific mutations are particularly prevalent in
Sardinia (11–34 %) (Guiso et al. 1996), Sicily (10 %)
(Lukens 1993), Greece (5–15 %) (Lukens 1993), and also
in Iran (4–10 %) (Haghshenas and Zamani 1997).
Previous studies have estimated the prevalence of the β-
thalassemia trait in Iran above 10 % around the Caspian Sea
and the Persian Gulf, and about 4–8 % in other areas
(Haghshenas and Zamani 1997).
Overall, in a report of the Iranian Ministry’s of health from
2008, the average frequency of β-thalassemia trait for the
whole of the country has been estimated to be 3.6 % (Iranian
Health 2008). This would mean that without premarital
screening the national birth prevalence would be at least
1,300 affected newborns per year (Iranian Health 2008). On
the other hand, due to the high rate of consanguineous mar-
riages in the Iranian population (30–80 %), predicting the
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Fig. 3 Marriage refusal rate
among screened couples with
thalassemia trait and suspected
couples in Isfahan Province
within 1992–2010
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Fig. 4 Frequency of genetic
testing (PND1) among under-
care couples with thalassemia
trait in Isfahan Province
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prevalence for beta-thalassemia trait in Iran becomes more
complex.
According to the prevalence of carrier couples with beta-
thalassemia trait among screened couples in our study
(∼0.31 %), we can calculate an expected prevalence of β-
thalassemia trait in general population about 5.6 % for
Isfahan Province (
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:31%
p
), but it would be less than this
percentage taking into account an estimated consanguinity
of 30–40 % for Isfahan’s population (Mehrabi and
Zeyghami 2005; Hashemipour et al. 2007).
Genetic testing
The introduction of genetic testing has gone through quite a
few difficulties. The first genetic laboratory in Isfahan be-
came available in 2000, in the private sector. However, prior
2007 genetic testing remained accessible to a few couples
only because of discrepancies in price between the private
and public sectors, and insurance companies paying only a
fraction of the private sector’s costs.
Although genetic testing was officially free in the public
sector, only a few labs were functional and could accept
only a few couples.
On the other hand, only a few teams were available for
genetic counseling in the Province until 2007, and some
districts had no genetic counseling center (Iranian Health
2004). So, just a few carrier couples were referred for
genetic testing.
By the beginning of 2007, steps were taken to promote
quantity and quality of genetic counseling centers. So, all
districts within the province had at least a genetic counseling
center with a trained team that included a physician and an
expert counselor by the end of 2007. Moreover, financial
contracts were signed between the Iranian Health Ministry
and some genetic laboratories in the private sector to facil-
itate acceptance of genetic testing by the at risk couples.
This process was accelerated when the first public genetic
laboratory was established in the Isfahan Province in 2008.
As a result, the rate of genetic testing increased from 6.4 %
in the first of 2007 to 85 % at the end of 2010.
The considerable number of suspected couples at risk im-
poses an additional burden on the healthcare system, even
though most of them (over 80 % based on our study) will not
require special services after genetic testing. All together, the
number of suspected couples compared with the real carrier
couples confirmed by high HbA2 (more than 3.5 %, according
to the national guideline) was to high during the first decade of
beginning the program, probably due to genetic counseling
inadequacy and incomplete iron-therapy of suspected couples.
We have been however able to better select suspected couples
and decrease false positive during recent years. So, the propor-
tion of screened suspected couples to confirmed carrier couples
has decreases from 6.7 in 2004 to 3.9 in 2009 and 2010.
Effects on birth prevalence
In one study in Southern Iran, the birth prevalence of beta-
thalassemia major was 253 cases per 100,000 births in 1995
and 82 per 100,000 births in 2004 (Karimi et al. 2007).
Table 2 Frequency of causes that major beta-thalassemia patients
were born within 1997–2010 in Isfahan Province
Causes Number
of cases
Percent
Marriage before starting program 56 51.4
Culture related 16 14.7
Genetic counseling inadequacy 10 9.2
Healthcare inadequacy 7 6.4
Screening testing errors 5 4.6
Economic related 3 2.8
Non-referring from marriage
registration offices
2 1.8
Loss to follow up of carriers 2 1.8
Delay to genetic testing 2 1.8
Genetic testing errors 4 3.7
Unknown 2 1.8
Total 109 100.0
Fig. 5 Incidence rate of major beta-thalassaemia in Isfahan Province within 1997–2010
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Based on our results, the birth prevalence of major beta-
thalassemia in the Isfahan Province was much less than in
Southern Iran, but it decreased by about 29 fold at the end of
2010 compared with 1997, when the premarital screening
program was introduced in the Iranian Healthcare System.
Our analysis revealed however 109 affected births between
1997 and 2010 and indicated five major reasons for the
occurrence of new cases:
1. culture-related causes in 16 cases (30.2 %), leading to
refusal to have genetic testing
2. genetic counseling inadequacy in 10 cases (18.9 %)
3. inadequate healthcare, due to negligence in seven cases
(13.2 %)
4. screening testing errors in five cases (9.4 %)
5. economic-related causes in three cases (5.7 %) although
couples would have chosen for genetic testing and ther-
apeutic abortion (Wong et al. 2011)
Our data reveal that no new cases were born because of
inadequate genetic counseling or healthcare after 2004.
The five births attributable to screening testing errors
were born before 2000, during the first years of setting up
the program. Quality control for the screening labs has
solved this problem. The three cases due to economic prob-
lems occurred before 2005, when government funds for
genetic testing were not available at the present level.
Unfortunately some problems are still present in insurance
coverage of genetic testing particularly within the private
sector.
Conclusions
Although the Iranian premarital screening program for thalas-
semia has attained excellent results in control and prevention,
much remains to be done to improve the program.
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